
Owkin and Merck enter collaboration agreement for AI-powered cancer diagnostics
Betsy Goodfellow | December 20, 2023 | News story | Research and Development |ย ย AI diagnostics, Cancer, MSD, Merck, Oncology, Owkinย
Owkin and Merck, known as MSD outside of the US and Canada, have announced that they have entered into a collaboration agreement for the development and commercialisation of AI-powered digital pathology diagnostics for the European Union (EU) market.
The collaboration has a focus on developing a pre-screening procedure to improve testing rates for MSI-H in endometrial, gastric, small intestinal and biliary cancers, with the collaboration initially focused in the EU.
Owkin also intends to expand the development of these AI diagnostics into four new cancer types.
Meriem Sefta, chief diagnostics officer at Owkin, commented: โThis strategic alliance with MSD is focused on improving the way patients are diagnosed and receive treatment, advancing our shared mission of supporting healthcare providers in their adoption of innovative digital diagnostics. It is clear that there is a need for AI diagnostics that can both ease bottlenecks and resource pressures while also ramping up biomarker testing to match patients with optimal treatments.โ
Scott K Pruitt, associate vice president and head of Translational Oncology at MSD Research Laboratories, added: โThe application of AI technologies holds tremendous potential in the screening of patients and the diagnosis of disease. We look forward to working with the Owkin team toward harnessing this opportunity to identify more patients with MSI-H cancers who may benefit from ICI therapy.โ
Betsy Goodfellow
Related Content

Central nervous system cancer metastases โ the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds

BioMed X and Servier launch Europeโs first XSeed Labs to advance AI-powered antibody design
BioMed X and Servier have announced the launch of Europeโs first XSeed Labs research project, …

T-cell therapy โ the evolution of cancer treatments
The current forms of immunotherapy, how T cell therapy works and what the future holds






